European Union Regulation on pediatric medicines comes into force

15 January 2007

Following a European Parliamentary vote last summer in favor of a final Regulation for Pediatric Medicines, this legislation was adopted at the end of last year and comes into force on January 26 (Marketletters passim). The Regulation aims to establish a legislative framework that will fulfil the following main objectives:

- increased availability of medicines specifically adapted and licensed for use in the pediatric population;

- increased information available to the patient/carer and prescriber about the use of medicines in children, including clinical trial data; and

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight